Frequently Asked Questions about COVID-19 vaccines for people with pre-existing allergic conditions

Frequently Asked Questions about COVID-19 vaccines for people with pre-existing allergic conditions

Updated 01 April 2022

The National Immunisation Advisory Committee (NIAC) together with the Irish Association of Allergy and Immunology (IAAI) have produced a Frequently Asked Questions (FAQ) document about COVID-19 vaccines for people with pre-existing allergic conditions.

The Frequently Asked Questions (FAQ) document, available to view and download below, has been created to aid vaccinators and other front-line healthcare professionals. The document provides information on how to advise allergic individuals according to their specific allergy history.

It provides guidance regarding five COVID-19 vaccines: mRNA vaccines (Cominarty (Pfizer-BioNTech), Spikevax (formerly COVID-19 Vaccine Moderna)), adenoviral vector vaccines (COVID-19 Vaccine Janssen, Vaxzevria (formerly COVID-19 Vaccine AstraZeneca)), and protein sub unit vaccine (Nuvaxovid (Novavax)).

Frequently Asked Questions about COVID-19 vaccines for people with pre-existing allergic conditions

Updated 01 April 2022